The Importin9/RANBP9 antibody targets a multifunctional adaptor protein involved in diverse cellular processes. RANBP9 (Ran-binding protein 9), also known as Importin9. belongs to the importin β superfamily and plays roles in nucleocytoplasmic transport, signaling pathways, and cytoskeletal organization. It interacts with Ran GTPase, a key regulator of nuclear import/export, suggesting its involvement in classical nuclear transport mechanisms governed by the Ran-GTP gradient. Structurally, RANBP9 contains SPRY, LISH, and CRA domains that mediate interactions with partners like growth factor receptors (e.g., EGFR), cell cycle regulators, and tumor suppressors (e.g., p53).
Antibodies against RANBP9/Importin9 are vital tools for studying its localization, expression, and molecular interactions. They are widely used in techniques such as Western blotting, immunofluorescence, and co-immunoprecipitation to explore its roles in cancer progression, viral infection (e.g., HIV), and neurodegenerative diseases (e.g., Alzheimer’s). Dysregulation of RANBP9 is linked to tumorigenesis, metastasis, and synaptic dysfunction, making it a potential therapeutic target. Researchers also investigate its isoform-specific functions and post-translational modifications, which may influence antibody specificity. Commercial antibodies vary in performance depending on epitope regions and experimental conditions, necessitating validation via knockout controls or siRNA-based approaches. Overall, these antibodies provide critical insights into RANBP9’s dual roles in transport and signaling networks.